Christopher Wasco DO, Zeryab Khan DO, Aimee Willett DO, Andrew Volio DO, Cody Carter DO, Aditya Kesari DO, Shaili Kothari MD, Andrew Scheidemantel DO, Katelyn Bennett DO, Jessalyn Schafer DO, Marie Lockhart PhD, Nagesh Chopra MD
{"title":"因心悸而转诊的 18-40 岁患者中高血压的发病率和流行率,心电图检查结果正常","authors":"Christopher Wasco DO, Zeryab Khan DO, Aimee Willett DO, Andrew Volio DO, Cody Carter DO, Aditya Kesari DO, Shaili Kothari MD, Andrew Scheidemantel DO, Katelyn Bennett DO, Jessalyn Schafer DO, Marie Lockhart PhD, Nagesh Chopra MD","doi":"10.1111/jch.14813","DOIUrl":null,"url":null,"abstract":"<p>Sixteen percent of patients referred for cardiology evaluation are found to have no cause for palpitations. Studies show that hypertension intricately influences “heart rate” and “contractility,?” the key components of “palpitation.” While the prevalence of hypertension is 22.4% in 18–39-year-olds, the relationship between palpitations and hypertension remains unknown in this age group. In our study, we assessed the incidence and prevalence of hypertension over 5 years in 18–40-year-olds referred for palpitations who had no known arrhythmic cause for palpitations between January 1, 206 and December 31, 2017. We found that over a period of 2.2 (0.7–4.1) years, an additional 56% patients were diagnosed with stage 1 (65/130) and stage 2 (28/130) hypertension, increasing the prevalence from 16% at the start of the study period to 72% at the end of the study period (<i>p</i> < .0001). Hypertensive patients were obese (BMI: 29 [24–36] kg/m<sup>2</sup> vs. 25 [22–31] kg/m<sup>2</sup>; <i>p</i> = .03), used nonsteroidal anti-inflammatory drugs (NSAIDs) (62 vs. 35%; <i>p</i> = .04), had a stronger family history of hypertension (55 vs. 4%; <i>p</i> < .0001) and exhibited higher systolic (124[120–130] mmHg vs. 112[108–115] mmHg; <i>p</i> < .0001) and diastolic (80[76–83] mmHg vs. 72[69–75] mmHg; <i>p</i> < .0001) blood pressures. Hypertension is commonly diagnosed in 18–40-year-old predominantly white female patients referred for palpitations without a known arrhythmic cause. The possibility of untreated hypertension causing palpitations in this cohort needs further evaluation.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jch.14813","citationCount":"0","resultStr":"{\"title\":\"Incidence and prevalence of hypertension in 18–40-year-old patients referred for palpitations with normal cardiac monitor findings\",\"authors\":\"Christopher Wasco DO, Zeryab Khan DO, Aimee Willett DO, Andrew Volio DO, Cody Carter DO, Aditya Kesari DO, Shaili Kothari MD, Andrew Scheidemantel DO, Katelyn Bennett DO, Jessalyn Schafer DO, Marie Lockhart PhD, Nagesh Chopra MD\",\"doi\":\"10.1111/jch.14813\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Sixteen percent of patients referred for cardiology evaluation are found to have no cause for palpitations. Studies show that hypertension intricately influences “heart rate” and “contractility,?” the key components of “palpitation.” While the prevalence of hypertension is 22.4% in 18–39-year-olds, the relationship between palpitations and hypertension remains unknown in this age group. In our study, we assessed the incidence and prevalence of hypertension over 5 years in 18–40-year-olds referred for palpitations who had no known arrhythmic cause for palpitations between January 1, 206 and December 31, 2017. We found that over a period of 2.2 (0.7–4.1) years, an additional 56% patients were diagnosed with stage 1 (65/130) and stage 2 (28/130) hypertension, increasing the prevalence from 16% at the start of the study period to 72% at the end of the study period (<i>p</i> < .0001). Hypertensive patients were obese (BMI: 29 [24–36] kg/m<sup>2</sup> vs. 25 [22–31] kg/m<sup>2</sup>; <i>p</i> = .03), used nonsteroidal anti-inflammatory drugs (NSAIDs) (62 vs. 35%; <i>p</i> = .04), had a stronger family history of hypertension (55 vs. 4%; <i>p</i> < .0001) and exhibited higher systolic (124[120–130] mmHg vs. 112[108–115] mmHg; <i>p</i> < .0001) and diastolic (80[76–83] mmHg vs. 72[69–75] mmHg; <i>p</i> < .0001) blood pressures. Hypertension is commonly diagnosed in 18–40-year-old predominantly white female patients referred for palpitations without a known arrhythmic cause. The possibility of untreated hypertension causing palpitations in this cohort needs further evaluation.</p>\",\"PeriodicalId\":50237,\"journal\":{\"name\":\"Journal of Clinical Hypertension\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-04-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jch.14813\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Hypertension\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/jch.14813\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Hypertension","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jch.14813","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
摘要
在转诊接受心脏病学评估的患者中,有 16% 的人被发现没有心悸的原因。研究表明,高血压会对 "心率 "和 "收缩力 "产生错综复杂的影响,而这正是 "心悸 "的关键组成部分。在 18-39 岁的人群中,高血压的发病率为 22.4%,但在这一年龄组中,心悸与高血压之间的关系仍然未知。在我们的研究中,我们评估了 206 年 1 月 1 日至 2017 年 12 月 31 日期间因心悸而转诊的 18-40 岁人群中 5 年内高血压的发病率和患病率,这些人的心悸没有已知的心律失常原因。我们发现,在2.2(0.7-4.1)年的时间里,又有56%的患者被诊断为1期(65/130)和2期(28/130)高血压,患病率从研究开始时的16%上升到研究结束时的72%(p <.0001)。高血压患者体型肥胖(体重指数:29 [24-36] kg/m2 vs. 25 [22-31] kg/m2; p = .03),使用非甾体抗炎药(NSAIDs)(62 vs. 35%; p = .04),有较强的高血压家族史(55 vs. 4%; p <.0001)。4%;p = 0.0001),收缩压(124[120-130] mmHg vs. 112[108-115] mmHg;p = 0.0001)和舒张压(80[76-83] mmHg vs. 72[69-75] mmHg;p = 0.0001)较高。因心悸而转诊的 18-40 岁以白人为主的女性患者中,高血压通常被诊断为心律失常。在这一人群中,未经治疗的高血压导致心悸的可能性需要进一步评估。
Incidence and prevalence of hypertension in 18–40-year-old patients referred for palpitations with normal cardiac monitor findings
Sixteen percent of patients referred for cardiology evaluation are found to have no cause for palpitations. Studies show that hypertension intricately influences “heart rate” and “contractility,?” the key components of “palpitation.” While the prevalence of hypertension is 22.4% in 18–39-year-olds, the relationship between palpitations and hypertension remains unknown in this age group. In our study, we assessed the incidence and prevalence of hypertension over 5 years in 18–40-year-olds referred for palpitations who had no known arrhythmic cause for palpitations between January 1, 206 and December 31, 2017. We found that over a period of 2.2 (0.7–4.1) years, an additional 56% patients were diagnosed with stage 1 (65/130) and stage 2 (28/130) hypertension, increasing the prevalence from 16% at the start of the study period to 72% at the end of the study period (p < .0001). Hypertensive patients were obese (BMI: 29 [24–36] kg/m2 vs. 25 [22–31] kg/m2; p = .03), used nonsteroidal anti-inflammatory drugs (NSAIDs) (62 vs. 35%; p = .04), had a stronger family history of hypertension (55 vs. 4%; p < .0001) and exhibited higher systolic (124[120–130] mmHg vs. 112[108–115] mmHg; p < .0001) and diastolic (80[76–83] mmHg vs. 72[69–75] mmHg; p < .0001) blood pressures. Hypertension is commonly diagnosed in 18–40-year-old predominantly white female patients referred for palpitations without a known arrhythmic cause. The possibility of untreated hypertension causing palpitations in this cohort needs further evaluation.
期刊介绍:
The Journal of Clinical Hypertension is a peer-reviewed, monthly publication that serves internists, cardiologists, nephrologists, endocrinologists, hypertension specialists, primary care practitioners, pharmacists and all professionals interested in hypertension by providing objective, up-to-date information and practical recommendations on the full range of clinical aspects of hypertension. Commentaries and columns by experts in the field provide further insights into our original research articles as well as on major articles published elsewhere. Major guidelines for the management of hypertension are also an important feature of the Journal. Through its partnership with the World Hypertension League, JCH will include a new focus on hypertension and public health, including major policy issues, that features research and reviews related to disease characteristics and management at the population level.